Better Quantum Computing Stock: IonQ vs. D-Wave

IonQ is presented as the relatively safer quantum-computing investment versus D-Wave, supported by 99.99% 2-qubit gate fidelity and an agreement to install its Superion 256 system at Nvidia's Accelerated Quantum Research Center. IonQ generated $145 million of first-half 2026 revenue versus $28 million a year earlier, but its operating loss widened to $1.06 billion from $210 million and its shares are down more than one-third over the past year; its P/S ratio is about 65. D-Wave's first-half revenue fell 67% year over year to $5.9 million, with a $66 million loss and an approximately 475x P/S multiple, leading the article to advise risk-averse investors to avoid both stocks while favoring IonQ if choosing between them.

Analysis

The relevant divergence is not “quantum exposure” but monetization quality: IONQ’s larger revenue base and NVDA integration can support a premium versus QBTS, yet neither company has demonstrated that bookings convert into recurring, high-margin compute revenue. The reported IONQ loss/revenue relationship implies acquisition, R&D, and infrastructure costs are scaling materially faster than commercial output; absent a sharp improvement in backlog quality and gross margin, partnership headlines are more likely to expand the multiple than alter intrinsic value.

NVDA’s economic exposure is immaterial near term, but its ecosystem endorsement may redirect enterprise quantum pilots toward trapped-ion architectures and away from annealing. That is a competitive problem for QBTS: optimization use cases may be commercially tangible, but they can often be addressed by improving classical solvers, GPUs, or hybrid software before customers commit to specialized quantum hardware. T and other enterprise case studies should be treated as proof-of-concept marketing until contract value, renewal rates, and deployment scale are disclosed.

Over the next 1-3 months, IONQ can outperform QBTS on incremental NVDA-related announcements, benchmark validation, or bookings disclosures, while QBTS remains vulnerable to financing concerns if cash burn persists. Over 6-18 months, the decisive catalyst is not qubit fidelity but a disclosed multi-year backlog, utilization growth, and gross-margin trajectory. The contrarian risk is that IONQ’s relative “safety” becomes crowded: at an already elevated revenue multiple, even strong topline growth will not protect the stock if guidance fails to establish a credible path to operating leverage.

Key Decisions for Investors

• Express the relative thesis via long IONQ / short QBTS in equal dollar amounts over a 1-3 month horizon; use a 15% adverse spread stop. The trade works if ecosystem validation and enterprise procurement favor IONQ, but fails if QBTS reports material recurring bookings or a strategic partner validates annealing economics.
• Do not add outright IONQ exposure solely on NVDA partnership headlines. Upgrade only after earnings show contracted backlog growth, improving gross margin, and annualized operating-expense growth below revenue growth; without these data, the position is momentum rather than fundamental.
• For existing QBTS holders, reduce into strength and monitor cash runway, ATM issuance, and quarterly bookings rather than revenue distorted by hardware-system timing. A new capital raise or another weak recurring-revenue print is the likely 1-6 month downside catalyst.
• Maintain NVDA as the cleaner quantum-adjacent exposure rather than using it as a direct quantum trade: upside from quantum tooling is optionality, while the core AI compute earnings base limits binary technology-adoption risk. No material earnings impact should be assumed from IONQ deployments in the next 12 months.